ExodusPoint Capital Management LP Acquires 143,077 Shares of Phreesia, Inc. (NYSE:PHR)

ExodusPoint Capital Management LP lifted its stake in Phreesia, Inc. (NYSE:PHR - Free Report) by 448.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 174,971 shares of the company's stock after buying an additional 143,077 shares during the period. ExodusPoint Capital Management LP owned about 0.30% of Phreesia worth $4,402,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in PHR. The Manufacturers Life Insurance Company lifted its position in shares of Phreesia by 3.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company's stock worth $637,000 after acquiring an additional 905 shares during the period. MetLife Investment Management LLC raised its stake in shares of Phreesia by 3.8% in the third quarter. MetLife Investment Management LLC now owns 30,781 shares of the company's stock valued at $701,000 after purchasing an additional 1,120 shares in the last quarter. R Squared Ltd bought a new position in Phreesia in the fourth quarter worth $30,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Phreesia by 9.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,015 shares of the company's stock worth $319,000 after buying an additional 1,258 shares in the last quarter. Finally, BankPlus Trust Department acquired a new stake in Phreesia during the fourth quarter worth $34,000. 92.10% of the stock is owned by institutional investors and hedge funds.

Phreesia Price Performance

Phreesia stock traded up $0.06 on Friday, reaching $24.06. The company's stock had a trading volume of 472,952 shares, compared to its average volume of 434,961. The business's fifty day moving average price is $26.57 and its 200 day moving average price is $24.26. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. The company has a market cap of $1.41 billion, a price-to-earnings ratio of -16.37 and a beta of 0.82. Phreesia, Inc. has a twelve month low of $17.07 and a twelve month high of $30.53.

Insider Buying and Selling

In other news, General Counsel Allison C. Hoffman sold 4,585 shares of the business's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $26.90, for a total transaction of $123,336.50. Following the completion of the sale, the general counsel now owns 154,552 shares in the company, valued at $4,157,448.80. The trade was a 2.88 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Evan Roberts sold 1,785 shares of the firm's stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $26.98, for a total value of $48,159.30. Following the completion of the transaction, the chief operating officer now owns 768,208 shares in the company, valued at approximately $20,726,251.84. This represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 176,963 shares of company stock worth $4,920,321 in the last 90 days. Corporate insiders own 5.80% of the company's stock.

Wall Street Analyst Weigh In

PHR has been the subject of a number of analyst reports. Piper Sandler reaffirmed an "overweight" rating and set a $33.00 price objective (up from $31.00) on shares of Phreesia in a report on Wednesday, January 29th. Canaccord Genuity Group raised their price target on shares of Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a research note on Thursday, March 13th. Royal Bank of Canada raised Phreesia from a "sector perform" rating to an "outperform" rating and lifted their price objective for the company from $24.00 to $32.00 in a report on Wednesday, January 8th. Needham & Company LLC reissued a "buy" rating and issued a $29.00 target price on shares of Phreesia in a report on Thursday, March 13th. Finally, KeyCorp boosted their price target on Phreesia from $28.00 to $30.00 and gave the company an "overweight" rating in a research note on Wednesday, January 8th. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $31.33.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.